RBC Capital Mkts has recently raised Sarepta Therapeutics Inc (SRPT) stock to Outperform rating, as announced on July 29, 2024, according to Finviz. Earlier, on June 26, 2024, Citigroup had reduced the stock from a Buy to Neutral, setting a price target of $176 for SRPT stock. Piper Sandler also initiated Overweight rating with a price target of $157. Additionally, RBC Capital Mkts reduced Sector Perform rating on May 28, 2024, with a target price of $142. Oppenheimer analysts, in their report published on May 14, 2024, also raised Outperform rating and set a price target of $180 for Sarepta Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sarepta Therapeutics Inc (SRPT) Stock Trading Recap
On Friday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $120.4 which represents a slight increase of $1.64 or 1.38% from the prior close of $118.76. The stock opened at $119.91 and touched a low of $118.63 during the day, reaching a high of $121.88. The volume of shares traded was 0.89 million falling short of the average volume of 1.03 million.
Sponsored
SRPT Stock Performance and Moving Averages
In recent trading, Sarepta Therapeutics Inc (SRPT) stock price has shown some volatility, fluctuating -3.32% over the last five trades and -9.99% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -4.51%, and it has plunged by -20.51% in the previous three months. Currently, SRPT is trading at -3.84%, -9.64%, and -6.04% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, SRPT, a Healthcare sector stock, is trading -30.51% below its 52-week high but remains 117.92% above its 52-week low. The Average True Range (ATR) (14 days) of 3.63 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Sarepta Therapeutics Inc’s Profitability and Valuation Ratios
Sarepta Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 2.52% and a profit margin of 3.14%, with a gross margin of -4.51%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Sarepta Therapeutics Inc’s market capitalization stands at $11.48 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The stock’s price-to-earnings (P/E) ratio is 297.65, assessing the company’s valuation relative to its earnings. The forward P/E ratio, which uses projected earnings for the next financial year, is 10.73. Additionally, the Price-to-Sales Ratio is 7.63, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 10.65, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 6.13% of Sarepta Therapeutics Inc (SRPT)’s shares, while financial institutions hold 92.36%.
Notable insider trades include Estepan Ian Michael, Chief Financial Officer at Sarepta Therapeutics Inc (SRPT), who sold 5985 shares on Aug 30 ’24, at $137.36 each, totaling $0.82 million. On Jun 25 ’24, Brown Ryan Edward, EVP, General Counsel, sold 38957 shares for $161.61 each, amounting to $6.30 million. Additionally, on Jun 24 ’24, Arif Bilal sold 7859 shares at $163.08 each, generating $1.28 million.
